BR112018075396A2 - dengue neutralizing antibody for use in a method of preventing and / or treating Zika infection - Google Patents

dengue neutralizing antibody for use in a method of preventing and / or treating Zika infection

Info

Publication number
BR112018075396A2
BR112018075396A2 BR112018075396-3A BR112018075396A BR112018075396A2 BR 112018075396 A2 BR112018075396 A2 BR 112018075396A2 BR 112018075396 A BR112018075396 A BR 112018075396A BR 112018075396 A2 BR112018075396 A2 BR 112018075396A2
Authority
BR
Brazil
Prior art keywords
residues
flaviviruses
zika
denv
virus
Prior art date
Application number
BR112018075396-3A
Other languages
Portuguese (pt)
Inventor
Rey Félix
Barba Spaeth Giovanna
Vaney Marie-Christine
Rouvinski Alexander
Screaton Gavin
MONGKOLSAPAYA Juthathip
Original Assignee
Imperial Innovations Ltd
Institut Pasteur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imperial Innovations Ltd, Institut Pasteur filed Critical Imperial Innovations Ltd
Publication of BR112018075396A2 publication Critical patent/BR112018075396A2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/18—Togaviridae; Flaviviridae
    • C07K14/1816—Flaviviridae, e.g. pestivirus, mucosal disease virus, bovine viral diarrhoea virus, classical swine fever virus (hog cholera virus), border disease virus
    • C07K14/1825—Flaviviruses or Group B arboviruses, e.g. yellow fever virus, japanese encephalitis, tick-borne encephalitis, dengue
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1081—Togaviridae, e.g. flavivirus, rubella virus, hog cholera virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24171—Demonstrated in vivo effect
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

trata-se de um epítopo de dímero de envelope (ede) de flavivírus para uso em vacinação de um indivíduo contra um ou mais flavivírus em que o ede é um flavivírus recombinante estabilizado, opcionalmente dímero de ectodomínio e (se) de glicoproteína de envelope de zika e/ou vírus da dengue, em que o dímero é: covalentemente estabilizado com pelo menos uma ligação intercadeia de dissulfeto entre os dois monômeros de se, e/ou não covalentemente estabilizado com a substituição de pelo menos um resíduo de aminoácido na sequência de aminoácidos de pelo menos um monômero de se por pelo menos um aminoácido de cadeia lateral volumoso na interface de dímero ou no ligante de domínio 1 (d1)/domínio 3 (d3) de cada monômero, covalentemente estabilizado com pelo menos um reticulador reativo à sulfidrila entre os dois monômeros de se, e/ou covalentemente estabilizado através da formação como uma cadeia de polipeptídeos única, opcionalmente com uma região de ligante, opcionalmente uma região de ligante rica em serina e glicina, que separa as sequências de se, e/ou covalentemente estabilizado pela ligação dos dois monômeros de se através de açúcares modificados; e/ou, em que o dímero é um homodímero ou heterodímero de polipeptídeos de envelope mutantes e/ou nativos, de qualquer um ou dois dentre denv-1, denv-2, denv-3, denv-4, zika ou outros flavivírus; e em que o um ou mais flavivírus são selecionados a partir de vírus da zika; vírus da zika e vírus da dengue; vírus da zika e outros flavivírus; flavivírus além da dengue. o ede pode ser um homodímero ou heterodímero de polipeptídeos de envelope mutantes e/ou nativos de qualquer um ou dois dentre denv-1, denv-2, denv-3, denv-4 e zika. anticorpo neutralizante isolado ou fragmento de ligação ao antígeno direcionado contra o ede, conforme definido em qualquer uma das reivindicações 1 a 29, em que, opcionalmente, o dito anticorpo ou fragmento do mesmo liga os cinco segmentos de polipeptídeo do ectodomínio e (se) de glicoproteína de vírus da dengue que consistem nos resíduos 67 a 74, resíduos 97 a 106, resíduos 307 a 314, resíduos 148 a 159 e resíduos 243 a 251 ou resíduos correspondentes do ectodomínio e de glicoproteína de vírus da zika ou flavivírus ou que consistem em zika pf13 resíduos 67 a 77, resíduos 97 a 106, resíduos 313 a 315, resíduos 243 a 253, resíduo k373 ou resíduos correspondentes do ectodomínio e de glicoproteína de flavivírus, em que, opcionalmente, a ligação não é afetada pela presença ou ausência de glicano de dengue n153 (zika n154) ou resíduo correspondente, para uso em um método para prevenção e/ou tratamento de infecção por um ou mais flavivírus, em que o um ou mais flavivírus são selecionados a partir de vírus da zika; vírus da zika e vírus da dengue; vírus da zika e outros flavivírus; flavivírus além da dengue.This is a flavivirus envelope dimer (ede) epitope for use in vaccinating an individual against one or more flaviviruses wherein the ede is a stabilized recombinant flavivirus, optionally ectodomain dimer and (if) glycoprotein envelope (s). zika and / or dengue virus, wherein the dimer is: covalently stabilized with at least one disulfide interlinkage bond between the two monomers of se, and / or non-covalently stabilized with the substitution of at least one amino acid residue in the sequence. amino acids of at least one monomer and at least one bulky side chain amino acid at the dimer interface or domain 1 (d1) / domain 3 (d3) linker of each monomer, covalently stabilized with at least one sulfhydryl reactive crosslinker between the two monomers of each other, and / or covalently stabilized by forming as a single polypeptide chain, optionally with a ligand region. and, optionally a serine and glycine-rich linker region, which separates the se sequences and / or covalently stabilized by the binding of the two se monomers via modified sugars; and / or wherein the dimer is a homodimer or heterodimer of native and / or mutant envelope polypeptides of any one or two of denv-1, denv-2, denv-3, denv-4, zika or other flaviviruses; and wherein one or more flaviviruses are selected from Zika virus; Zika virus and dengue virus; Zika virus and other flaviviruses; flaviviruses besides dengue. The ede may be a homodimer or heterodimer of mutant and / or native envelope polypeptides of either one or two of denv-1, denv-2, denv-3, denv-4 and zika. isolated neutralizing antibody or ede-directed antigen-binding fragment as defined in any one of claims 1 to 29, wherein optionally said antibody or fragment thereof binds the five ectodomain and (if) polypeptide segments. dengue virus glycoprotein consisting of residues 67 to 74, residues 97 to 106, residues 307 to 314, residues 148 to 159 and residues 243 to 251 or corresponding residues of ectodomain and glycoprotein of Zika virus or flavivirus or consisting of zika pf13 residues 67 to 77, residues 97 to 106, residues 313 to 315, residues 243 to 253, residues k373 or corresponding ectodomain and flavivirus glycoprotein residues, where optionally binding is not affected by the presence or absence of dengue glycan n153 (zika n154) or corresponding residue, for use in a method for preventing and / or treating infection with one or more flaviviruses, wherein the one or more flaviviruses are selected from Zika virus; Zika virus and dengue virus; Zika virus and other flaviviruses; flaviviruses besides dengue.

BR112018075396-3A 2016-06-10 2017-06-09 dengue neutralizing antibody for use in a method of preventing and / or treating Zika infection BR112018075396A2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1610162.8 2016-06-10
GBGB1610162.8A GB201610162D0 (en) 2016-06-10 2016-06-10 Methods
PCT/GB2017/051692 WO2017212291A1 (en) 2016-06-10 2017-06-09 Neutralising antibody against dengue for use in a method of prevention and/or treatment of zika infection

Publications (1)

Publication Number Publication Date
BR112018075396A2 true BR112018075396A2 (en) 2019-03-19

Family

ID=56894660

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018075396-3A BR112018075396A2 (en) 2016-06-10 2017-06-09 dengue neutralizing antibody for use in a method of preventing and / or treating Zika infection

Country Status (8)

Country Link
US (2) US11111274B2 (en)
EP (1) EP3468591A1 (en)
JP (1) JP2019523647A (en)
BR (1) BR112018075396A2 (en)
CA (1) CA3066488A1 (en)
GB (1) GB201610162D0 (en)
MX (1) MX2018015343A (en)
WO (1) WO2017212291A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201605394SA (en) 2007-09-26 2016-08-30 Chugai Pharmaceutical Co Ltd Modified Antibody Constant Region
EP3494991A4 (en) 2016-08-05 2020-07-29 Chugai Seiyaku Kabushiki Kaisha Composition for prophylaxis or treatment of il-8 related diseases
SG10201607778XA (en) 2016-09-16 2018-04-27 Chugai Pharmaceutical Co Ltd Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
BR112020008652A2 (en) 2017-11-03 2020-11-10 Takeda Vaccines, Inc. Zika vaccines and immunogenic compositions and methods of using them
AU2018375173B2 (en) 2017-11-30 2022-08-25 Takeda Vaccines, Inc. Zika vaccines and immunogenic compositions, and methods of using the same
TWI827585B (en) * 2018-03-15 2024-01-01 日商中外製藥股份有限公司 Anti-dengue virus antibodies having cross-reactivity to zika virus and methods of use
EP3870208A4 (en) * 2018-10-26 2022-10-26 New York Blood Center, Inc. Zika virus immunogenic compositions
WO2020242388A1 (en) * 2019-05-28 2020-12-03 Chiang Mai University Mature virus-like particles of flaviviruses
TWI756812B (en) * 2019-09-03 2022-03-01 財團法人國家衛生研究院 Multiple mosquito-borne flavivirus vaccine and use thereof in inducing neutralizing antibodies
JP7471555B2 (en) * 2020-02-20 2024-04-22 国立感染症研究所長 Flavivirus cross-neutralizing antibodies and pharmaceutical compositions
WO2023235660A2 (en) * 2022-05-17 2023-12-07 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Flavivirus immunogens and vaccine compositions and methods of using the same
WO2024081625A1 (en) * 2022-10-11 2024-04-18 University Of Maryland, Baltimore Engineered flavivirus envelope glycoprotein immunogenic compositions and methods of use

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
CA2576798C (en) 2004-07-27 2014-09-09 Gwong-Jen J. Chang Localization and characterization of flavivirus envelope glycoprotein cross-reactive epitopes and methods for their use
CU23586A1 (en) * 2005-11-22 2010-10-30 Ct Ingenieria Genetica Biotech METHODS AND PROTEINS FOR THE PROPHLACTIC AND / OR THERAPEUTIC TREATMENT OF THE FOUR SEROTYPES OF THE DENGUE VIRUS AND OTHER FLAVIVIRUS
GB201413086D0 (en) * 2014-07-23 2014-09-03 Imp Innovations Ltd And Inst Pasteur Methods

Also Published As

Publication number Publication date
GB201610162D0 (en) 2016-07-27
US20190256560A1 (en) 2019-08-22
JP2019523647A (en) 2019-08-29
US11111274B2 (en) 2021-09-07
MX2018015343A (en) 2019-11-18
EP3468591A1 (en) 2019-04-17
US11926648B2 (en) 2024-03-12
CA3066488A1 (en) 2017-12-14
WO2017212291A1 (en) 2017-12-14
US20210355167A1 (en) 2021-11-18

Similar Documents

Publication Publication Date Title
BR112018075396A2 (en) dengue neutralizing antibody for use in a method of preventing and / or treating Zika infection
BR112017001340A2 (en) antidengue vaccines and antibodies
HRP20210874T1 (en) Immunomodulatory proteins with tunable affinities
BR112019010699A2 (en) t-cell receptors and immunotherapy employing the same
PE20211272A1 (en) IL-22 POLYPEPTIDES AND IL-22 Fc FUSION PROTEINS AND METHODS OF USE
BR112018007318A2 (en) isolated antibody or antigen binding fragment, pharmaceutical composition, and methods for treating a disease or condition.
BR112016016411A2 (en) "Fc"-REGION VARIANTS WITH MODIFIED "FcRn" BINDING PROPERTIES
BR122020006914B8 (en) ANTI-TNF-ALFA SINGLE DOMAIN ANTIBODY AND ITS USE, IN VITRO METHODS FOR MEASURING SAID ANTIBODY LEVELS AND FOR DIAGNOSING A DISORDER MEDIATED BY AN INTRACELLULAR COMPONENT, ISOLATED POLYPEPTIDE, AND COMPOSITION COMPRISING SUCH ANTIBODY OR ISOLATED POLYPEPTIDE
RU2021124437A (en) CONSTRUCTIONS AIMED AT THE AFP / MHC PEPTIDE COMPLEXES AND THEIR USES
CY1119976T1 (en) Calcitonin Mimics for the Treatment of Diseases and Disorders
PE20191551A1 (en) DESIGNED TRANSFERRIN RECEPTOR BINDING POLYPEPTIDES
PE20190352A1 (en) GDF 15 FUSION PROTEINS AND USES OF THEM
JOP20190248A1 (en) Trem2 antigen binding proteins and uses thereof
PE20221909A1 (en) ANTIGEN-BINDING MOLECULES COMPRISING A LIGAND TRIMER OF THE TNF FAMILY
BR112017017029A2 (en) degradable thiolene polymers and methods for their manufacture
BR112018073511A2 (en) glucagon receptor selective polypeptides and methods of use
BR112014012808A2 (en) anticancer fusion protein
BR112018071686A2 (en) membrane integral protein display in enveloped extracellular poxvirus virions
AR102595A1 (en) ANTI-ANG2 ANTIBODIES AND METHODS OF USE
BR112018007960A2 (en) conjugate, pcrv protein, immunogenic composition, methods of preparing an immunogenic composition, treating and producing a bioconjugate, polynucleotide, vector, host cell, and, bioconjugate.
BR112018003594A2 (en) recombinant immunoglobulin heavy chain, antibodies, conjugate production method and conjugates
PE20190371A1 (en) BETA INTERFERON ANTIBODIES AND USES OF THEM
BR112017017609A2 (en) fc fusion protein, and pharmaceutical composition.
JP2014506452A5 (en)
PE20181956A1 (en) POLYPEPTIDES THAT INHIBIT CD40L

Legal Events

Date Code Title Description
B15V Prolongation of time limit allowed

Free format text: TENDO EM VISTA A PORTARIA INPI PR NO 120 DE 16/03/2020, PORTARIA INPI PR NO 161 DE 13/04/2020; PORTARIA INPI PR NO 166 DE 27/04/2020 E PORTARIA INPI PR NO 179 DE 11/05/2020, QUANTO A SUSPENSAO DOS PRAZOS VENCIDOS ENTRE 16/03/2020 A 31/05/2020, DEVOLVE-SE O PRAZO NESSE PEDIDO COM RELACAO A SOLICITACAO DO PEDIDO DE EXAME.

B25G Requested change of headquarter approved

Owner name: INSTITUT PASTEUR (FR) ; IMPERIAL INNOVATIONS LTD (GB)

B25A Requested transfer of rights approved

Owner name: INSTITUT PASTEUR (FR) ; IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY AND MEDICINE (GB)

B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]